Eric Sagonowsky

Editor

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in November 2014 and covers topics such as drug pricing, biosimilars and product liability litigation.

Stories by Eric Sagonowsky

Baltimore sues J&J for 'sham' litigation to defend Zytiga

by Eric Sagonowsky

Wednesday, May 22, 2019

J&J's med should have faced generics years ago, a lawsuit claims, but J&J used underhanded tactics to keep cheaper copycats at bay.

Johnson & Johnson's good news, bad news day in talc court

by Eric Sagonowsky

Wednesday, May 22, 2019

As J&J continues to defend against allegations its talc powders can cause cancer, it prevailed in a South Carolina trial and lost in New York on Tuesday.

Merck Fosamax case gets another shot at preemption argument

by Eric Sagonowsky

Tuesday, May 21, 2019

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its case.

AbbVie discounting Humira to support Skyrizi rollout: analyst

by Eric Sagonowsky

Monday, May 20, 2019

AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch, an analyst writes.

AZ's Fasenra benefits hold up for 2 years: analysis

by Eric Sagonowsky

Monday, May 20, 2019

AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.

Gilead's O'Day takes congressional hot seat to defend Truvada

by Eric Sagonowsky

Friday, May 17, 2019

Gilead's Truvada for PrEP is only getting to about 10% of people who could benefit, according to testimony Thursday.

Evolus' promotional Cancun bash sparks controversy

by Eric Sagonowsky

Thursday, May 16, 2019

Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun, Mexico.

Gilead schemed with J&J, BMS to protect HIV combos: lawsuit

by Eric Sagonowsky

Wednesday, May 15, 2019

Gilead has reaped billions of dollars in sales from "unlawfully monopolized" HIV drugs, patients and activists say in a new class action lawsuit.

D.C. officials weigh abandoning rebate proposal: BioCentury

by Eric Sagonowsky

Wednesday, May 15, 2019

Officials from both parties have come up with a possible alternative to HHS' rebate-nixing idea: an out-of-pocket cap in Medicare Part D.

Gilead tries—and fails—to bail out of HIV drug safety lawsuit

by Eric Sagonowsky

Tuesday, May 14, 2019

Gilead must face claims that it delayed developing its safer, next-generation HIV meds to reap as much revenue as possible from its older drugs.